Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Classement en actions #5435
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the... AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
Prix de l'action
$169.98
Dernière synchronisation: 2026-09-25
Capitalisation boursière
$2.64B
Changement (1 jour)
0.69%
Changement (1 an)
16.30%
Pays
GB
Échange AstraZeneca PLC (AZN)

Catégorie

Marge opérationnelle de AstraZeneca PLC (AZN)
Marge opérationnelle au September 2026 TTM : 22.69%
Selon les derniers rapports financiers et le cours de l'action de AstraZeneca PLC, la marge opérationnelle actuelle (TTM) est de 22.69%. À la fin de 2023, elle était de 20.54%.
Historique de la marge opérationnelle pour AstraZeneca PLC de 2000 à 2026
Marge opérationnelle à la fin de chaque année
Année Marge opérationnelle Changez
2026 (TTM) 22.69% -4.06%
2024 23.65% 15.14%
2023 20.54% 80.02%
2022 11.41% 50.73%
2021 7.57% -55.42%
2020 16.98% 47.52%
2019 11.51% 38.51%
2018 8.31% -46.21%
2017 15.45% -0.26%
2016 15.49% 6.90%
2015 14.49% 3.95%
2014 13.94% -41.77%
2013 23.94% -24.38%
2012 31.66% -12.49%
2011 36.18% -4.69%
2010 37.96% 8.15%
2009 35.10% 11.39%
2008 31.51% 11.78%
2007 28.19% -3.85%
2006 29.32% 9.73%
2005 26.72% 31.24%
2004 20.36% -6.65%
2003 21.81% -10.69%
2002 24.42% 1.79%
2001 23.99% 18.59%
2000 20.23% 0.00%
Marge opérationnelle pour des entreprises similaires ou concurrentes
Entreprise Marge opérationnelle Différence de Marge Opérationnelle Pays
43.92% -98.06%
US
26.81% -98.82%
US
29.32% -98.71%
US
26.59% -98.83%
CH
16.65% -99.27%
US
Qu'est-ce que la Marge opérationnelle d'une entreprise ?
La Marge opérationnelle est un indicateur clé pour évaluer la rentabilité d'une entreprise. Une marge d'exploitation plus élevée est généralement préférable car elle montre qu'une entreprise peut vendre ses produits ou services bien au-dessus de leurs coûts de production. Elle se calcule en divisant les bénéfices par le chiffre d'affaires.